FDA: Potential Contamination in Some Liquid Pharma Products

Share this content:
FDA: Potential Contamination in Some Liquid Pharma Products
FDA: Potential Contamination in Some Liquid Pharma Products

WEDNESDAY, Aug. 16, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has announced a recall of numerous liquid pharmaceutical products because of possible bacterial contamination that could cause severe infections in vulnerable patients.

The drugs and dietary supplements, made by PharmaTech LLC in Davie, Fla., include liquid stool softeners, liquid vitamin D drops, and liquid multivitamins marketed for infants and children, the agency said in a news release. Reports of the discovery of Burkholderia cepacia bacteria in both Diocto Liquid and Diocto Syrup prompted the voluntary recall by three companies that label PharmaTech products, the FDA said. The three companies are Rugby Laboratories, Major Pharmaceuticals, and Leader Brands.

"B. cepacia poses a serious threat to vulnerable patients, including infants and young children who still have developing immune systems," FDA Commissioner Scott Gottlieb, M.D., said in a statement. "These products were distributed nationwide to retailers, health care facilities, pharmacies, and sold online -- making it important that parents, patients, and health care providers be made aware of the potential risk and immediately stop using these products."

The FDA advises patients and physicians to stop using these products immediately. Consumers with questions can contact Rugby Laboratories/Major Pharmaceuticals at 800-645-2158, or Leader at 800-200-6313.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »